ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,025.99
-0.95%
Dow Jones
44,303.40
-0.99%
US Dollar vs MXN
20.5715
0.00%
Brent Oil
74.565
0.00%
Bitcoin
96,230.32
-0.33%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Syndax Pharmaceuticals Inc (SNDX) Cotización

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc (SNDX)

NASDAQ
15.52
-0.30
(-1.90%)
Cerrado 07 Febrero 3:00PM
Delayed by 15 minutes
15.52
0.00
(0.00%)
Fuera de horario: 5:55PM
Delayed by 15 minutes

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Estadísticas y detalles clave

Último Precio
15.52
Postura de Compra
14.98
Postura de Venta
16.00
Volume Operado de la Acción
2,884,028
15.20 Rango del Día 16.16
12.06 Rango de 52 semanas 25.34
Capitalización de Mercado [m]
1.325B
Precio Anterior
15.82
Precio de Apertura
15.82
Hora
65
@
15.99
Última hora de negociación
Volumen financiero
US$ 44,985,611
Precio Promedio Ponderado
15.5982
Volumen promedio (3 m)
2,437,411
Acciones en circulación
85,357,675
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-6.33
Beneficio por acción (BPA)
-2.45
turnover
-
Beneficio neto
-209.36M

Acerca de Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and ... Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.syndax.com
Sede
Wilmington, Delaware, USA
Fundado
-
Syndax Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SNDX. The last closing price for Syndax Pharmaceuticals was US$15.82. Over the last year, Syndax Pharmaceuticals shares have traded in a share price range of US$ 12.06 to US$ 25.34.

Syndax Pharmaceuticals currently has 85,357,675 shares in issue. The market capitalisation of Syndax Pharmaceuticals is US$1.35 billion. Syndax Pharmaceuticals has a price to earnings ratio (PE ratio) of -6.33.

Flujo de Opciones Syndax Pharmaceuticals (SNDX)

Ver flujo de opciones completo

Flujo General

Optimista

Prima Neta

121k

Calls / Puts

100.00%

Comp. / Vent.

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

SNDX Últimas noticias

Más noticias

Form 4 - Statement of changes in beneficial ownership of securities

8 horas hace
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

8 horas hace
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

8 horas hace
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

8 horas hace
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

8 horas hace
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

8 horas hace
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

8 horas hace
Edgar (US Regulatory)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., Feb. 4, 2025 WALTHAM, Mass., Feb. 4, 2025 /PRNewswire/ -- Syndax Pharmaceuticals...

04 Febrero 2025
PR Newswire (US)

Syndax Announces Participation in February Investor Conferences

Syndax Announces Participation in February Investor Conferences PR Newswire WALTHAM, Mass., Jan. 30, 2025 WALTHAM, Mass., Jan. 30, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a...

30 Enero 2025
PR Newswire (US)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

22 Enero 2025
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
11.158.002783576914.3716.5813.64300461714.82986131CS
41.7913.037144938113.7316.5812.06225239114.12983127CS
12-1.21-7.2325164375416.7317.512.06243741114.34825581CS
26-4.82-23.697148475920.3422.512.06167041116.02538965CS
52-7.06-31.266607617422.5825.3412.06138247018.32799066CS
1560.362.374670184715.1629.8611.215109932118.91034646CS
2605.758.04480651739.8229.866.8889786718.77175306CS

SNDX - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Syndax Pharmaceuticals?
El precio actual de las acciones de Syndax Pharmaceuticals es US$ 15.52
¿Cuántas acciones de Syndax Pharmaceuticals están en circulación?
Syndax Pharmaceuticals tiene 85,357,675 acciones en circulación
¿Cuál es la capitalización de mercado de Syndax Pharmaceuticals?
La capitalización de mercado de Syndax Pharmaceuticals es USD 1.35B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Syndax Pharmaceuticals?
Syndax Pharmaceuticals ha negociado en un rango de US$ 12.06 a US$ 25.34 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Syndax Pharmaceuticals?
El ratio precio/beneficio de Syndax Pharmaceuticals es -6.33
¿Cuál es la moneda de reporte de Syndax Pharmaceuticals?
Syndax Pharmaceuticals presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Syndax Pharmaceuticals?
El último beneficio anual de Syndax Pharmaceuticals es USD -209.36M
¿Cuál es la dirección registrada de Syndax Pharmaceuticals?
La dirección registrada de Syndax Pharmaceuticals es 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
¿Cuál es la dirección del sitio web de Syndax Pharmaceuticals?
La dirección del sitio web de Syndax Pharmaceuticals es www.syndax.com
¿En qué sector industrial opera Syndax Pharmaceuticals?
Syndax Pharmaceuticals opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
MGOLMGO Global Inc
US$ 0.4191
(126.54%)
816.59M
CDTConduit Pharmaceuticals Inc
US$ 2.831
(82.65%)
144.17M
GSIWGarden Stage Ltd
US$ 0.79
(78.73%)
219.64M
TOIIWOncology Institute Inc
US$ 0.033
(58.88%)
7.27k
CYTHCyclo Therapeutics Inc
US$ 1.19
(54.55%)
84.73M
FTELFitell Corporation
US$ 2.70
(-57.01%)
2.3M
SGBXSafe and Green Holdings Corporation
US$ 0.6401
(-44.82%)
5.65M
NKLANikola Corporation
US$ 0.4432
(-41.10%)
52.44M
PLRXPliant Therapeutics Inc
US$ 7.785
(-34.85%)
6.44M
LIPOLipella Pharmaceuticals Inc
US$ 3.08
(-33.76%)
2.2M
MGOLMGO Global Inc
US$ 0.4191
(126.54%)
780.46M
RIMEAlgorhythm Holdings Inc
US$ 0.0169
(-20.66%)
262.79M
GSIWGarden Stage Ltd
US$ 0.79
(78.73%)
215.16M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0537
(14.74%)
210.78M
NVDANVIDIA Corporation
US$ 129.84
(0.90%)
209.04M

SNDX Discussion

Ver más
dinogreeves dinogreeves 5 meses hace
Have you looked at TIL on Friday.
👍️0
Monksdream Monksdream 5 meses hace
SNDX a buy again
👍️0
dinogreeves dinogreeves 1 año hace
SNDX had the highest volume today for some reason, this is either going to tank hard on Monday or hit 30...50....60 dollars. Took my chances with 600 shares.
👍️0
dinogreeves dinogreeves 1 año hace
Possibly a huge run on Monday, very possible or they missed the trial. Huge 400 million in the coffers and monster institutional ownership.
👍️0
dealerschool2006 dealerschool2006 4 años hace
Nice rebound today for $SNDX, beat the street and conference call was successful!!!
👍️0
dealerschool2006 dealerschool2006 4 años hace
SNDX recovering from panic sale!!!
👍️0
dealerschool2006 dealerschool2006 4 años hace
Panic sale for SNDX on positive results...May options wide swings...
👍️0
DaytraderJohn DaytraderJohn 5 años hace
Its interesting how a company such as this can go on to have revenue loss of 50m+ per year. Yet still give higher ups 200k+ cash bonuses and large salaries.

They have no product revenue.

I expect shares to be diluted after earnings.

Read their 10k. I guess it's a gamble play incase one day they do get approval.
👍️0
BoilerRoom BoilerRoom 5 años hace
$SNDX looks like this run is going to continue. Let’s hit $15.00 this week folks
👍️0
ClayTrader ClayTrader 5 años hace
* * $SNDX Video Chart 01-31-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
BoilerRoom BoilerRoom 5 años hace
$SNDX next week is going to be fun
👍️0
BoilerRoom BoilerRoom 5 años hace
$SNDX Hope you guys went all in here...Have a great weekend see y’all on Monday
👍️0
BoilerRoom BoilerRoom 5 años hace
$SNDX holding this baby!
👍️0
BoilerRoom BoilerRoom 5 años hace
$SNDX keep climbing baby! Going be going up all next week
👍️0
BoilerRoom BoilerRoom 5 años hace
$SNDX looking awesome from my call at $8.00
👍️0
BoilerRoom BoilerRoom 5 años hace
$SNDX got us a runner folks!!!
👍️0
BoilerRoom BoilerRoom 5 años hace
$SNDX Chomp Chomp Chomp!
👍️0
BoilerRoom BoilerRoom 5 años hace
$SNDX Weeeeeeeeeee
👍️0
BoilerRoom BoilerRoom 5 años hace
Going to run folks.
👍️0
BoilerRoom BoilerRoom 5 años hace
$SNDX in at $8.00
👍️0
TheFinalCD TheFinalCD 5 años hace
News News Alert: Syndax Announces $35.0 Million Offering of Common Stock...
👍️0
whytestocks whytestocks 6 años hace
News: $SNDX Syndax Announces $26.2 Million Offering of Common Stock and Warrants

WALTHAM, Mass. , March 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with Biotechnolo...

Find out more https://marketwirenews.com/news-releases/syndax-announces-26-2-million-offering-of-common-stock-and-warrants-7897910.html
👍️0
DewDiligence DewDiligence 6 años hace
SNDX 3Q18 results—cash=$89.6M:

https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-third-quarter-2018-financial-results-and-provides-clinical-and-business-update-300744153.html
👍️0
Spartak Spartak 6 años hace
Well, the company is done. What a disaster.
👍️0
DewDiligence DewDiligence 6 años hace
SNDX -21%/AH on PFS failure in HR+/HER2- breast cancer:

https://finance.yahoo.com/news/syndax-host-conference-call-phase-200500374.html

The trial continues to test for statsig OS every six months until Nov 2019.
👍️0
DewDiligence DewDiligence 6 años hace
SNDX -20% on no news—sell-off could be related to recent general bearishness for PD-(L1) add-on agents, which was a theme at ESMO.
👍️0
DewDiligence DewDiligence 6 años hace
SNDX upgrades BoD:

https://www.prnewswire.com/news-releases/syndax-announces-changes-to-its-board-of-directors-300718661.html
👍️0
DewDiligence DewDiligence 6 años hace
#msg-143766395
👍️0
DewDiligence DewDiligence 6 años hace
SNDX phase-3 PFS data now expected in 4Q18 (rather than 3Q18); I essentially called this back in May (#msg-140923103, bottom):

https://www.prnewswire.com/news-releases/syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-pembrolizumab-in-non-small-cell-lung-cancer-300717717.html
👍️0
DewDiligence DewDiligence 6 años hace
#msg-143642544
👍️0
DewDiligence DewDiligence 6 años hace
SNDX 2Q18 CC transcript:

https://finance.yahoo.com/news/edited-transcript-sndx-earnings-conference-152734163.html
👍️0
DewDiligence DewDiligence 7 años hace
SNDX 2Q18 items—6/30/18 cash=$98.4M…

PR:
http://ir.syndax.com/news-releases/news-release-details/syndax-pharmaceuticals-reports-second-quarter-2018-financial

CC slides:
http://ir.syndax.com/static-files/18eaf63a-6c93-45cd-8272-60479300c153
👍️0
Spartak Spartak 7 años hace
When does pounding stop? Someone hummers it pretty badly.
👍️0
fsantes fsantes 7 años hace
Ill keep a look out for some then!... I’ve been looking as well. Thank you!
👍️0
DewDiligence DewDiligence 7 años hace
No. I generally post anything that's material.
👍️0
fsantes fsantes 7 años hace
Have you heard any new news on SNDX?
👍️0
fsantes fsantes 7 años hace
I really appreciate it. Bought some shares as one advisor mentioned it to me but keeping track of what’s going on on it
👍️0
DewDiligence DewDiligence 7 años hace
SNDX requested that the SEC keep this document in redacted form:

https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/sndx-ex101_169.htm

This was filed as an exhibit to the most recent 10-Q.
👍️0
fsantes fsantes 7 años hace
Do you know what’s the news that came out about? When I look it’s blank..
👍️0
DewDiligence DewDiligence 7 años hace
SNDX, NKTR ink clinical-trial collaboration for Entinostat + NK-214 in second-lime melanoma:

https://www.prnewswire.com/news-releases/syndax-and-nektar-therapeutics-announce-immuno-oncology-clinical-trial-collaboration-300656793.html

NKTR is furnishing free drug for the phase-1/2 clinical trial, but no cash.
👍️0
DewDiligence DewDiligence 7 años hace
SNDX ENCORE-601 update…

PR:
https://www.prnewswire.com/news-releases/syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-pembrolizumab-300650233.html

CC slides:
http://ir.syndax.com/static-files/7c0c8627-0b81-43d6-9210-6cb02684db5f
👍️0
tika1 tika1 7 años hace
After failure of two high profile IO combination, I think SNDX will go nowhere for its own IO combo.

All eyes on Etinostat + exemestane only. Still chance of double, if that turns out good.
👍️0
DewDiligence DewDiligence 7 años hace
Transcript of SNDX 1Q18 CC:

https://finance.yahoo.com/news/edited-transcript-sndx-earnings-conference-235620976.html
👍️0
DewDiligence DewDiligence 7 años hace
SNDX new investor slide set:

http://ir.syndax.com/static-files/da19e99b-2bd2-4456-91fe-0e67b97fc0d0
👍️0
DewDiligence DewDiligence 7 años hace
The 1Q18 10-Q has been filed:

https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/sndx-10q_20180331.htm
👍️0
DewDiligence DewDiligence 7 años hace
SNDX 1Q18 results—cash=$113M:

https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-first-quarter-2018-financial-results-and-provides-clinical-and-business-update-300644832.html
👍️0
DewDiligence DewDiligence 7 años hace
SNDX ASCO lineup:

https://finance.yahoo.com/news/syndax-pharmaceuticals-announces-presentations-2018-200500073.html
👍️0
DewDiligence DewDiligence 7 años hace
Yes—please see my reply in #msg-140012720.
👍️0
tika1 tika1 7 años hace
Dew,
Is there any hope for success of this trial after high profile INCY failure? What is your take on SNDX current weakness?


Oral Presentations:

Title: Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial
Presenter: Anthony W. Tolcher, M.D.
Category: Clinical Trials
Session: Biomarkers in Immuno-oncology
Abstract Number: CT179
Location: N Hall C - McCormick Place North (Level 1)
Date and Time: Tuesday April 17, 2018; 3:50 PM - 4:05 PM C.T.
👍️0
DewDiligence DewDiligence 7 años hace
SNDX presentation lineup at AACR:

https://finance.yahoo.com/news/syndax-present-2018-american-association-110000742.html
👍️0

Su Consulta Reciente

NASDAQ
SNDX
Syndax Pharmaceuticals
AQSE
CMGU.GB
UBS
AQSE
VUSD.GB
Vanguard S&p 500 Ucits Etf
BIT
CTEK
Global X Cleantech UCITS...
BIT
SIFXS5
Societe Generale Effekten
BIT
CBUS
Ubs Lux Fund Sol - Bbg U...
BIT
MMS
ETF
ASX
MEQ
Metlifecare
BIT
P1OCG5
BNP Paribas Issuance
BIT
P1QJF7
BNP Paribas Issuance
BIT
F17857
Vontobel Financial Produ...
AQSE
HEV
Helium Ventures
BIT
XT01
Xtrackers Treasuries Ult...
COIN
UCAUSD
Ucacoin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios